Early trial links daraxonrasib chemo combo to tumor control in metastatic pancreatic cancer
Fox News reports early phase 1/2 trial results presented in Barcelona: 61 untreated metastatic pancreatic cancer patients received daraxonrasib plus gemcitabine and nab-paclitaxel. Researchers reported tumors shrank in 60.7% and growth was halted in 90.2%.
This is HUB News’s original summary. Read the complete report at Fox News.